Pegaptanib octasodium
Macugen (pegaptanib octasodium) is an unknown pharmaceutical. Pegaptanib octasodium was first approved as Macugen on 2006-01-31. It has been approved in Europe to treat wet macular degeneration.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
193 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 3 | 16 | 8 | — | 29 |
| Depression | D003863 | F33.9 | — | 3 | 7 | 8 | 5 | 22 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 3 | 4 | 10 | 5 | 21 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 3 | 4 | 6 | 2 | 4 | 19 |
| Healthy volunteers/patients | — | 14 | — | — | 1 | 3 | 18 | ||
| Panic disorder | D016584 | EFO_0004262 | F41.0 | 1 | 1 | 2 | 6 | 5 | 15 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 6 | 1 | 3 | 3 | 1 | 14 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | 2 | 4 | 3 | 1 | 2 | 12 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 1 | 2 | 4 | 7 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | — | — | 2 | 3 | 6 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hot flashes | D019584 | 1 | 1 | 2 | — | 1 | 5 | ||
| Premature ejaculation | D061686 | HP_0012876 | F52.4 | — | — | 2 | — | 1 | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | — | — | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | 1 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | A41.9 | — | 1 | — | — | — | 1 | |
| Septic shock | D012772 | A48.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 2 | — | — | — | — | 2 |
| Hypercapnia | D006935 | 2 | — | — | — | — | 2 | ||
| Diabetic neuropathies | D003929 | EFO_1000783 | 1 | — | — | — | — | 1 | |
| Anovulation | D000858 | 1 | — | — | — | — | 1 | ||
| Phase i metabolic detoxication | D050216 | 1 | — | — | — | — | 1 | ||
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 2 | 2 | |
| Sleep wake disorders | D012893 | G47 | — | — | — | — | 2 | 2 | |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
| Hepatitis c | D006526 | B19.2 | — | — | — | — | 1 | 1 | |
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEGAPTANIB OCTASODIUM |
| INN | — |
| Description | Macugen (pegaptanib octasodium) is an unknown pharmaceutical. Pegaptanib octasodium was first approved as Macugen on 2006-01-31. It has been approved in Europe to treat wet macular degeneration. |
| Classification | Oligonucleotide |
| Drug class | angiogenesis inhibitors; aptamers, classical and mirror; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108752 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,308 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
57,679 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more